BUDGET IMPACT ANALYSIS OF VENETOCLAX FOR MANAGEMENT OF ACUTE MYELOID LEUKEMIA FROM THE PERSPECTIVE OF THE SOCIAL SECURITY AND THE PRIVATE SECTOR IN ARGENTINA

被引：0
|
作者：
Palacios, A. [1 ]
Espinola, N. [1 ]
Gonzalez, J. M. [1 ]
Rivas, M. M. [2 ]
Rojas-Roque, C. [1 ]
Kanevsky, D. [3 ]
Morisset, P. [3 ]
Augustovski, F. [1 ]
Pichon-Riviere, D. A. [1 ]
Bardach, A. [1 ]
机构：
[1] Inst Clin Effectiveness & Hlth Policy IECS, Buenos Aires, DF, Argentina
[2] Hosp Univ Austral, Pilar, Argentina
[3] AbbVie, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB43
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [41] BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Kim, H. S. J.
    Buehler, A.
    Matsuo, A. L.
    VALUE IN HEALTH, 2019, 22 : S462 - S462
  • [42] Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia
    Franco, Stephanie
    Geng, Xue
    Korostyshevskiy, Valeriy
    Karp, Judith E.
    Lai, Catherine
    CANCER, 2023, 129 (19) : 2975 - 2985
  • [43] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF VISCOSUPPLEMENTATION WITH ORTHOVISC™ (HYALURONAN) IN KNEE OSTEOARTHRITIS, FROM THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Rezende, M. U.
    Hernandez, A. J.
    Namba, M. M.
    Fernandes, R. A.
    Takemoto, M. L. S.
    Santos, P. M. L.
    Repsold, D. M.
    Silva, R. C.
    Andrade, P. C.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [44] A FIVE YEARS BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ADALIMUMAB FOR CROHN'S DISEASE PATIENTS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Menezes, F. G.
    Chibana, V
    VALUE IN HEALTH, 2015, 18 (07) : A663 - A663
  • [45] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF CROHN'S DISEASE FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SETTING
    Rosim, R. P.
    Duva, A. S.
    Ferraz, Ballalai A. F.
    Valle, A.
    Toth, E.
    Ferguson, S.
    Carmo, V. S. E.
    VALUE IN HEALTH, 2017, 20 (05) : A181 - A182
  • [46] Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT
    Canaani, Jonathan
    Labopin, Myriam
    Socie, Gerard
    Nihtinen, Anne
    Huynh, Anne
    Cornelissen, Jan
    Deconinck, Eric
    Gedde-Dahl, Tobias
    Forcade, Edouard
    Chevallier, Patrice
    Bourhis, Jean H.
    Blaise, Didier
    Mohty, Mohamad
    Nagler, Arnon
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) : 653 - 659
  • [47] Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative
    Vachhani, Pankit
    Wolach, Ofir
    Garcia, Jacqueline S.
    Zeidner, Joshua F.
    Talati, Chetasi
    Pollyea, Daniel A.
    Lai, Catherine
    Moshe, Yakir
    Abedin, Sameem
    Lavie, David
    Zuckerman, Tsila
    Xavier, Marin
    Lee, Sangmin
    Chen, Evan
    Edwards, Wesleigh
    Bui, Cat N.
    Svensson, Anders
    Kye, Steve
    Burne, Rebecca
    Maitland, Jessica
    Ma, Esprit
    Montez, Melissa
    Grunspan, Moshe
    Goldberg, Aaron D.
    BLOOD, 2021, 138
  • [48] Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective
    Huang, Xingyue
    Beresford, Eric
    Lodise, Thomas
    Friedland, H. David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (12) : 1057 - 1064
  • [49] BUDGET IMPACT ANALYSIS OF ORITAVANCIN FOR THE TREATMENT OF MODERATE TO SEVERE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) FROM A HOSPITAL PERSPECTIVE
    Garg, M.
    Venugopalan, V.
    Premraj, S.
    Park, H.
    VALUE IN HEALTH, 2018, 21 : S151 - S151
  • [50] Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
    Heiblig, Mael
    Requena, Gaspar Aspas
    Tauveron-Jalenques, Urbain
    Tavernier, Emmanuelle
    Cornillon, Jerome
    Carre, Martin
    Meunier, Mathieu
    Thevenet, Ugo
    Nadine, Boullanger Fow Heng
    Santana, Clemence
    Rocher, Clement
    Lamure, Sylvain
    Belhabri, Amine
    Michallet, Mauricette
    Contejean, Adrien
    Mauz, Natacha
    Pica, Gian Matteo
    Dony, Arthur
    Gross, Zofia
    BLOOD, 2024, 144 : 846 - 847
12345